ANTX - AN2 Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ANTX

AN2 THERAPEUTICS, INC.

NASDAQ

$4.40

▼ DOWN 5.98% (-0.28)

KEY STATISTICS

Market Cap$167.48 M

52w High$7.19

52w Low$1.00

Dividend Yield17.05%

FrequencyQuarterly

P/E-4.00

Volume442.13K

Shares Out.36.02M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Eric E. Easom

COMPENSATION 2026

Salary$603,750

Stock Awards$164,133

Incentive Plan Pay$332,063

All Other Comp.$7,500

Total$1,382,985

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 25, 2022

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$9.00

Target Low$9.00

Target Median$9.00

Target Consensus$9.00

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

36.13%

HOLDERS

TOP 8 OF 63 · RANKED BY POSITION SIZE

Millennium Management LLC

Adage Capital Partners Gp, L.L.C.

Boxer Capital Management, LLC

749.0K sh

$2.56M

PRICE

$4.40 ▼ DOWN 5.98% (−$0.28)

About AN2 Therapeutics, Inc.

https://www.an2therapeutics.com ↗

AN2 Therapeutics, Inc., a Menlo Park-based clinical-stage biopharmaceutical company founded in 2017, develops treatments for rare infectious diseases, including its oral drug epetraborole for chronic non-tuberculous mycobacterial lung disease.

INDUSTRY

Biotechnology

A PRODUCT AN2 THERAPEUTICS, INC. IS KNOWN FOR

AN2-502998

AN2 Therapeutics' lead in development, AN2-502998, is a boron-based oral small molecule in Phase 1 trials targeting chronic Chagas disease, following the discontinuation of a previous lead asset.

COMPETITORS

COMPETITOR

INSM COMPARE

MNKD COMPARE

SPRO COMPARE

AN2 Therapeutics in 2025

SENTIMENT: + POSITIVE

PARTNERSHIP · NOVEMBER 2025

AN2 Therapeutics Announces Research Collaboration with GSK to Advance Novel Tuberculosis Therapies

AN2 Therapeutics entered into a research collaboration with global biopharmaceutical company GSK to develop new boron-based treatments for tuberculosis (TB). This partnership leverages AN2's expertise in boron chemistry and is supported by a third year of funding from the Gates Foundation, highlighting the potential of their scientific platform to address a major global health challenge.

PARTNERSHIP · NOVEMBER 2025 · ANNOUNCED

AN2 Therapeutics Enters a Strategic Research Collaboration with GSK to Develop Novel Tuberculosis Therapies

AN2 Therapeutics announced a research collaboration with global biopharmaceutical company GSK to discover and develop new therapies for tuberculosis (TB) using AN2's proprietary boron chemistry platform. This partnership is also supported by a third year of funding from the Gates Foundation, highlighting a joint commitment to address this major global health challenge.